224 related articles for article (PubMed ID: 22926523)
1. GAB2 induces tumor angiogenesis in NRAS-driven melanoma.
Yang Y; Wu J; Demir A; Castillo-Martin M; Melamed RD; Zhang G; Fukunaga-Kanabis M; Perez-Lorenzo R; Zheng B; Silvers DN; Brunner G; Wang S; Rabadan R; Cordon-Cardo C; Celebi JT
Oncogene; 2013 Aug; 32(31):3627-37. PubMed ID: 22926523
[TBL] [Abstract][Full Text] [Related]
2. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.
Ding C; Luo J; Fan X; Li L; Li S; Wen K; Feng J; Wu G
J Exp Clin Cancer Res; 2017 Apr; 36(1):56. PubMed ID: 28420432
[TBL] [Abstract][Full Text] [Related]
3. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
Pang JM; Chien PC; Kao MC; Chiu PY; Chen PX; Hsu YL; Liu C; Liang X; Lin KT
PLoS One; 2023; 18(4):e0284744. PubMed ID: 37083947
[TBL] [Abstract][Full Text] [Related]
5. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
6. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
Ryan MB; Finn AJ; Pedone KH; Thomas NE; Der CJ; Cox AD
Mol Cancer Res; 2016 Oct; 14(10):1009-1018. PubMed ID: 27418645
[TBL] [Abstract][Full Text] [Related]
7. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
8. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
10. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
11. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
[TBL] [Abstract][Full Text] [Related]
12. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
13. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
17. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
18. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.
Duckworth C; Zhang L; Carroll SL; Ethier SP; Cheung HW
Oncogene; 2016 Aug; 35(31):4036-47. PubMed ID: 26657155
[TBL] [Abstract][Full Text] [Related]
20. Gab2-mediated signaling promotes melanoma metastasis.
Horst B; Gruvberger-Saal SK; Hopkins BD; Bordone L; Yang Y; Chernoff KA; Uzoma I; Schwipper V; Liebau J; Nowak NJ; Brunner G; Owens D; Rimm DL; Parsons R; Celebi JT
Am J Pathol; 2009 Apr; 174(4):1524-33. PubMed ID: 19342374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
